Literature DB >> 711332

Infections of congenitally athymic (nude) and normal mice with avirulent and virulent strains of Venezuelan encephalitis virus.

P A LeBlanc, W F Scherer, D H Sussdorf.   

Abstract

Two strains of Venezuelan encephalitis virus that are avirulent for normal BALB/c mice inoculated subcutaneously were also avirulent for infected congenitally athymic (nude) mice of the same strain. Viremias were of similar magnitudes and durations in normal and nude mice. Brain concentrations were higher in nude mice with the one avirulent strain tested, although the periods of detectable virus in brains were similar. No lesions were found in brains, spleens, or lymph nodes by ordinary histopathological examination. Viral neutralizing antibody titers in plasmas at 1 to 3 weeks after infection were lower and more transient in nude than in normal mice, and implantations of thymic tissues into nude mice partially restored their neutralizing antibody responses. Concentrations of spleen cells producing antibodies that lysed sheep erythrocytes 4 days after inoculation of erythrocytes and avirulent virus into nude mice were above the levels of uninfected nude mice. These concentrations were similar in infected and uninfected normal mice. In contrast, two mouse-virulent strains of Venezuelan encephalitis virus killed nude mice faster than normal mice after subcutaneous inoculation. Yet concentrations and durations of virus in bloods and brains were not consistently different between nude and normal mice. There were perivascular monocytes in brains and slight architectural alterations of spleens and lymph nodes. Concentrations of spleen cells producing antibodies hemolytic for sheep erythrocytes 4 days after inoculation with erythrocytes were depressed in nude and normal mice by infection with virulent strains.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 711332      PMCID: PMC422065          DOI: 10.1128/iai.21.3.779-785.1978

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  21 in total

1.  INAPPARENT VIRAL INFECTION OF CELLS IN VITRO. I. CONVERSION OF INAPPARENT TO APPARENT INFECTION BY ENVIRONMENTAL ALTERATION OF CHICKEN EMBRYONIC CELLS IN CULTURES INOCULATED WITH JAPANESE ENCEPHALITIS VIRUS.

Authors:  W F SCHERER
Journal:  Am J Pathol       Date:  1964-09       Impact factor: 4.307

2.  USE OF AN ATTENUATED STRAIN OF VENEZUELAN EQUINE ENCEPHALOMYELITIS VIRUS FOR IMMUNIZATION IN MAN.

Authors:  R W MCKINNEY; T O BERGE; W D SAWYER; W D TIGERTT; D CROZIER
Journal:  Am J Trop Med Hyg       Date:  1963-07       Impact factor: 2.345

3.  Plaque formation in agar by single antibody-producing cells.

Authors:  N K JERNE; A A NORDIN
Journal:  Science       Date:  1963-04-26       Impact factor: 47.728

4.  Studies on the virus of Venezuelan equine encephalomyelitis. II. Modification by specific immune serum of response of central nervous system of mice.

Authors:  T O BERGE; C A GLEISER; W S GOCHENOUR; M L MIESSE; W D TIGERTT
Journal:  J Immunol       Date:  1961-11       Impact factor: 5.422

5.  Nude mice--a model system for studying the cellular basis of the humoral immune response.

Authors:  B A Croy; D Osoba
Journal:  Cell Immunol       Date:  1973-11       Impact factor: 4.868

6.  The role of the thymus in antibody production and in resistance to Japanese encephalitis virus infection.

Authors:  R Mori; K Kimoto; K Takeya
Journal:  Arch Gesamte Virusforsch       Date:  1970

7.  Discovery and geographic distribution of Venezuelan encephalitis virus in Guatemala, Honduras, and British Honduras during 1965-68, and its possible movement to Central America and México.

Authors:  W F Scherer; R W Dickerman; J V Ordonez
Journal:  Am J Trop Med Hyg       Date:  1970-07       Impact factor: 2.345

8.  The influence of infection with Venezuelan equine encephalomyelitis virus on antibody response against sheep erythrocytes. I. Experiments on mice.

Authors:  J Hrusková; V Rychterová; V Kliment
Journal:  Acta Virol       Date:  1972-03       Impact factor: 1.162

9.  Enhanced humoral immunity in mice infected with attenuated Venezuelan equine encephalitis virus.

Authors:  R J Howard; C P Craig; G S Trevino; S F Dougherty; S E Mergenhagen
Journal:  J Immunol       Date:  1969-10       Impact factor: 5.422

10.  Immunological deficiency diseases. Agammaglobulinemia, hypogammaglobulinemia, Hodgkin's disease and sarcoidosis.

Authors:  R A GOOD; W D KELLY; J ROTSTEIN; R L VARCO
Journal:  Prog Allergy       Date:  1962
View more
  6 in total

1.  Role of alpha/beta interferon in Venezuelan equine encephalitis virus pathogenesis: effect of an attenuating mutation in the 5' untranslated region.

Authors:  L J White; J G Wang; N L Davis; R E Johnston
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

2.  Recombinant vaccinia virus/Venezuelan equine encephalitis (VEE) virus protects mice from peripheral VEE virus challenge.

Authors:  R M Kinney; J J Esposito; J H Mathews; B J Johnson; J T Roehrig; A D Barrett; D W Trent
Journal:  J Virol       Date:  1988-12       Impact factor: 5.103

3.  Mechanisms of protective immunogenicity of microbial vaccines: effects of cyclophosphamide pretreatment in Venezuelan encephalitis, Q fever and tularaemia.

Authors:  M S Ascher; P B Jahrling; D G Harrington; R A Kishimoto; V G McGann
Journal:  Clin Exp Immunol       Date:  1980-08       Impact factor: 4.330

4.  Resistance to alpha/beta interferons correlates with the epizootic and virulence potential of Venezuelan equine encephalitis viruses and is determined by the 5' noncoding region and glycoproteins.

Authors:  D R Spotts; R M Reich; M A Kalkhan; R M Kinney; J T Roehrig
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

5.  Attenuation of Venezuelan equine encephalitis virus strain TC-83 is encoded by the 5'-noncoding region and the E2 envelope glycoprotein.

Authors:  R M Kinney; G J Chang; K R Tsuchiya; J M Sneider; J T Roehrig; T M Woodward; D W Trent
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

6.  Application Route and Immune Status of the Host Determine Safety and Oncolytic Activity of Oncolytic Coxsackievirus B3 Variant PD-H.

Authors:  Ahmet Hazini; Babette Dieringer; Karin Klingel; Markian Pryshliak; Anja Geisler; Dennis Kobelt; Ole Daberkow; Jens Kurreck; Sophie van Linthout; Henry Fechner
Journal:  Viruses       Date:  2021-09-24       Impact factor: 5.048

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.